Literature DB >> 9247592

Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope.

T Kaneko1, T Moriyama, K Udaka, K Hiroishi, H Kita, H Okamoto, H Yagita, K Okumura, M Imawari.   

Abstract

An epitope that acted as a weak agonist in the cytotoxicity assay was identified as part of the capsid protein of a hepatitis C virus (HCV) variant. In a low concentration, the variant epitope also had a weak antagonistic effect. When a minute amount of this variant epitope was added to the culture for induction, it selectively attenuated the expansion of major cytotoxic T cell populations and drastically reduced the cytotoxic responses against the wild-type epitope. Thus, antagonism to induction suppressed immune responses against both the wild type and the variant, thereby helping the persistence of not only variant itself but also the wild-type HCV. Because this variant was a weak agonist, most cytotoxic T cells induced with the wild-type epitope were cross-reactive with the variant and susceptible to the antagonism to induction. Only the T cells which were not cross-reactive with the variant and not susceptible to the antagonism survived the antagonism in induction. This implied that the specificity of the remaining immune response, if any, was directed exclusively to the wild-type epitope after the emergence of the variant. For viruses like HCV, being heterogeneous itself may contribute significantly toward persistent infection through antagonism to induction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247592     DOI: 10.1002/eji.1830270728

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine.

Authors:  Toshie Mashiba; Keiko Udaka; Yasuko Hirachi; Yoichi Hiasa; Tomoya Miyakawa; Yoko Satta; Tsutomu Osoda; Sayo Kataoka; Michinori Kohara; Morikazu Onji
Journal:  Immunogenetics       Date:  2007-01-16       Impact factor: 2.846

4.  Hepatitis C virus core and envelope proteins do not suppress the host's ability to clear a hepatic viral infection.

Authors:  J Sun; F Bodola; X Fan; H Irshad; L Soong; S M Lemon; T S Chan
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.

Authors:  Yoichi Kimura; Toshifumi Gushima; Sharad Rawale; Pravin Kaumaya; Christopher M Walker
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.

Authors:  X Forns; R Thimme; S Govindarajan; S U Emerson; R H Purcell; F V Chisari; J Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Authors:  Javier Fernandez; Deborah Taylor; Duncan R Morhardt; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Stephen M Feinstone; Marian E Major
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 8.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

10.  Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load.

Authors:  Jing You; Lin Zhuang; Yi-Feng Zhang; Hong-Ying Chen; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Teerha Piratvisuth; Edward McNeil; Lan Yu; Bao-Zhang Tang; Jun-Hua Huang
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.